Verismo, a new cell therapy company pioneering multi-chain CAR-T technology, raised $16 million in equity financing. The company was co-founded by some of the same Penn Medicine scientists who helped to create and develop Kymriah, the first CAR-T product approved by the FDA. Penn Medicine faculty members Michael Milone, PhD, from Penn’s Center for Cellular Immunotherapy and Donald Siegel, PhD, director of the division of transfusion medicine and therapeutic pathology, re-purposed the CAR-T technology platform to create what Verismo now calls KIR-CAR, to potentially treat solid tumors. Penn Medicine’s CAR-T pioneer Dr. Carl June is also a founding advisor to the company.
